VIAF

Virtual International Authority File

Search

Leader 00000nz a2200037n 45 0
001 WKP|Q38293745 (VIAF cluster) (Authority/Source Record)
003 WKP
005 20241121000152.0
008 241121nneanz||abbn n and d
035 ‎‡a (WKP)Q38293745‏
024 ‎‡a 0000-0001-9501-4509‏ ‎‡2 orcid‏
024 ‎‡a 12446367900‏ ‎‡2 scopus‏
035 ‎‡a (OCoLC)Q38293745‏
046 ‎‡s 19000000‏
100 0 ‎‡a Evandro de Azambuja‏ ‎‡c researcher‏ ‎‡9 en‏
375 ‎‡a 1‏ ‎‡2 iso5218‏
400 0 ‎‡a Evandro de Azambuja‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400 0 ‎‡a Evandro de Azambuja‏ ‎‡c investigador‏ ‎‡9 ast‏
400 0 ‎‡a Evandro de Azambuja‏ ‎‡c ricercatore‏ ‎‡9 it‏
400 0 ‎‡a Evandro de Azambuja‏ ‎‡c investigador‏ ‎‡9 es‏
670 ‎‡a Author's 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial‏
670 ‎‡a Author's 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.‏
670 ‎‡a Author's 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial‏
670 ‎‡a Author's A pooled analysis of the cardiac events in the trastuzumab adjuvant trials‏
670 ‎‡a Author's Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.‏
670 ‎‡a Author's Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients‏
670 ‎‡a Author's Adjuvant chemotherapy in 2005: standards and beyond.‏
670 ‎‡a Author's Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial‏
670 ‎‡a Author's Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial‏
670 ‎‡a Author's Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer‏
670 ‎‡a Author's Adjuvant trastuzumab: a 10-year overview of its benefit.‏
670 ‎‡a Author's An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.‏
670 ‎‡a Author's An update on PARP inhibitors--moving to the adjuvant setting‏
670 ‎‡a Author's Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience‏
670 ‎‡a Author's Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).‏
670 ‎‡a Author's Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials‏
670 ‎‡a Author's Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.‏
670 ‎‡a Author's Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial‏
670 ‎‡a Author's Are we HER-ting for innovation in neoadjuvant breast cancer trial design?‏
670 ‎‡a Author's Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.‏
670 ‎‡a Author's Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial‏
670 ‎‡a Author's Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?‏
670 ‎‡a Author's Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence‏
670 ‎‡a Author's Beyond trastuzumab: new treatment options for HER2-positive breast cancer‏
670 ‎‡a Author's Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer‏
670 ‎‡a Author's Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors‏
670 ‎‡a Author's Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib‏
670 ‎‡a Author's Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.‏
670 ‎‡a Author's Breast cancer treatment-induced cardiotoxicity‏
670 ‎‡a Author's Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy‏
670 ‎‡a Author's Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study‏
670 ‎‡a Author's Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).‏
670 ‎‡a Author's Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?‏
670 ‎‡a Author's Cardiotoxicity of systemic agents used in breast cancer‏
670 ‎‡a Author's Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials‏
670 ‎‡a Author's Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology‏
670 ‎‡a Author's Career opportunities and benefits for young oncologists in the European Society for Medical Oncology‏
670 ‎‡a Author's Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).‏
670 ‎‡a Author's CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?‏
670 ‎‡a Author's CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion‏
670 ‎‡a Author's Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients‏
670 ‎‡a Author's Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.‏
670 ‎‡a Author's Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial‏
670 ‎‡a Author's Clinical practice-changing trials: the HERA study paradigm.‏
670 ‎‡a Author's CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial‏
670 ‎‡a Author's CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).‏
670 ‎‡a Author's Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.‏
670 ‎‡a Author's Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary‏
670 ‎‡a Author's Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).‏
670 ‎‡a Author's Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO)‏
670 ‎‡a Author's Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?‏
670 ‎‡a Author's Corrigendum to “Menopausal hormone therapy use in 17 European countries during the last decade” [Maturitas 79‏
670 ‎‡a Author's Corrigendum to “Menopausal hormone therapy use in 17 European countries during the last decade” [Maturitas 79 (2014) 287–291]‏
670 ‎‡a Author's Current perspectives of epothilones in breast cancer.‏
670 ‎‡a Author's Denosumab in early-stage breast cancer‏
670 ‎‡a Author's Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.‏
670 ‎‡a Author's Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial‏
670 ‎‡a Author's Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial‏
670 ‎‡a Author's Dissecting the heterogeneity of triple-negative breast cancer‏
670 ‎‡a Author's Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer‏
670 ‎‡a Author's Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients‏
670 ‎‡a Author's Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy‏
670 ‎‡a Author's Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial‏
670 ‎‡a Author's Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials‏
670 ‎‡a Author's Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.‏
670 ‎‡a Author's Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.‏
670 ‎‡a Author's End-of-life care: the red alert for physicians‏
670 ‎‡a Author's Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.‏
670 ‎‡a Author's Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis‏
670 ‎‡a Author's ER+/HER2+ breast cancer: are we really de-escalating?‏
670 ‎‡a Author's ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer‏
670 ‎‡a Author's Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.‏
670 ‎‡a Author's Facts and controversies in the use of trastuzumab in the adjuvant setting‏
670 ‎‡a Author's Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer‏
670 ‎‡a Author's Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.‏
670 ‎‡a Author's Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients‏
670 ‎‡a Author's Genomic grade adds prognostic value in invasive lobular carcinoma.‏
670 ‎‡a Author's Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer‏
670 ‎‡a Author's Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative‏
670 ‎‡a Author's Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†‏
670 ‎‡a Author's HER-2 as a target for breast cancer therapy.‏
670 ‎‡a Author's HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?‏
670 ‎‡a Author's HER2-overexpressing breast cancer: time for the cure with less chemotherapy?‏
670 ‎‡a Author's HER2-positive breast cancer is lost in translation: time for patient-centered research‏
670 ‎‡a Author's High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.‏
670 ‎‡a Author's How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer‏
670 ‎‡a Author's Hurdles and delays in access to anti-cancer drugs in Europe.‏
670 ‎‡a Author's I-SPY 2: optimising cancer drug development in the 21st century.‏
670 ‎‡a Author's Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis‏
670 ‎‡a Author's Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.‏
670 ‎‡a Author's Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer‏
670 ‎‡a Author's Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis‏
670 ‎‡a Author's Improving quality of life after breast cancer: dealing with symptoms‏
670 ‎‡a Author's In Reply to Belkacemi and Tsoutsou‏
670 ‎‡a Author's Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.‏
670 ‎‡a Author's International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).‏
670 ‎‡a Author's Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis‏
670 ‎‡a Author's Jumping higher: is it still possible? The ALTTO trial challenge‏
670 ‎‡a Author's Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial‏
670 ‎‡a Author's Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial‏
670 ‎‡a Author's Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response‏
670 ‎‡a Author's Larotaxel: broadening the road with new taxanes‏
670 ‎‡a Author's Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer‏
670 ‎‡a Author's Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.‏
670 ‎‡a Author's Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.‏
670 ‎‡a Author's Long-term toxic effects of adjuvant chemotherapy in breast cancer.‏
670 ‎‡a Author's Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant‏
670 ‎‡a Author's Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.‏
670 ‎‡a Author's Luminal B breast cancer: molecular characterization, clinical management, and future perspectives‏
670 ‎‡a Author's Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial‏
670 ‎‡a Author's Male breast cancer: finding the way in this uncommon path.‏
670 ‎‡a Author's Menopausal hormone therapy use in 17 European countries during the last decade‏
670 ‎‡a Author's Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries‏
670 ‎‡a Author's Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?‏
670 ‎‡a Author's Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation‏
670 ‎‡a Author's Molecular Profiling of a Tumor of Unknown Origin‏
670 ‎‡a Author's Molecular targeted therapies in breast cancer: where are we now?‏
670 ‎‡a Author's Motherhood after breast cancer: searching for la dolce vita.‏
670 ‎‡a Author's Multifactorial approach to predicting resistance to anthracyclines‏
670 ‎‡a Author's Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?‏
670 ‎‡a Author's Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy‏
670 ‎‡a Author's Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer‏
670 ‎‡a Author's Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri‏
670 ‎‡a Author's [Non-Hodgkin's lymphoma in the thyroid: case report]‏
670 ‎‡a Author's Novel therapeutics in breast cancer—Looking to the future‏
670 ‎‡a Author's Oncofertility counselling in premenopausal women with HER2-positive breast cancer‏
670 ‎‡a Author's OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy‏
670 ‎‡a Author's Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.‏
670 ‎‡a Author's Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†‏
670 ‎‡a Author's p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.‏
670 ‎‡a Author's Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial‏
670 ‎‡a Author's PERSEPHONE - implications for clinical practice in 2019‏
670 ‎‡a Author's Pertuzumab in HER2-positive early breast cancer: current use and perspectives‏
670 ‎‡a Author's Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients‏
670 ‎‡a Author's Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.‏
670 ‎‡a Author's Phosphoethanolamine and the danger of unproven drugs‏
670 ‎‡a Author's PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer‏
670 ‎‡a Author's Planning cancer control in Latin America and the Caribbean‏
670 ‎‡a Author's Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial‏
670 ‎‡a Author's Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis‏
670 ‎‡a Author's Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives‏
670 ‎‡a Author's Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial‏
670 ‎‡a Author's Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO‏
670 ‎‡a Author's Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials‏
670 ‎‡a Author's Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial‏
670 ‎‡a Author's Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).‏
670 ‎‡a Author's Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer‏
670 ‎‡a Author's Professional burnout in European young oncologists: results of the European Society for Medical Oncology‏
670 ‎‡a Author's Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.‏
670 ‎‡a Author's Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial‏
670 ‎‡a Author's Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98‏
670 ‎‡a Author's Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study‏
670 ‎‡a Author's Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy‏
670 ‎‡a Author's Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial‏
670 ‎‡a Author's Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol‏
670 ‎‡a Author's Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy‏
670 ‎‡a Author's Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?‏
670 ‎‡a Author's Recurrence dynamics of breast cancer according to baseline body mass index‏
670 ‎‡a Author's Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.‏
670 ‎‡a Author's Reply to C. Fontanella et al.‏
670 ‎‡a Author's Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients‏
670 ‎‡a Author's Review: side effects of approved molecular targeted therapies in solid cancers.‏
670 ‎‡a Author's Risk factors for the development of brain metastases in patients with HER2-positive breast cancer‏
670 ‎‡a Author's Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.‏
670 ‎‡a Author's RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.‏
670 ‎‡a Author's Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.‏
670 ‎‡a Author's Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant St‏
670 ‎‡a Author's Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge‏
670 ‎‡a Author's Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma‏
670 ‎‡a Author's Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.‏
670 ‎‡a Author's Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement‏
670 ‎‡a Author's Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?‏
670 ‎‡a Author's Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer‏
670 ‎‡a Author's Targeted therapies in breast cancer: are heart and vessels also being targeted?‏
670 ‎‡a Author's Targeted therapy for breast cancer in older patients‏
670 ‎‡a Author's Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer‏
670 ‎‡a Author's The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.‏
670 ‎‡a Author's The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study‏
670 ‎‡a Author's The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial‏
670 ‎‡a Author's The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)‏
670 ‎‡a Author's The landscape of medical oncology in Europe by 2020.‏
670 ‎‡a Author's The new generation of breast cancer clinical trials: the right drug for the right target‏
670 ‎‡a Author's The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.‏
670 ‎‡a Author's The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data‏
670 ‎‡a Author's The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.‏
670 ‎‡a Author's Threat posed by unproven drugs in medical oncology‏
670 ‎‡a Author's Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial‏
670 ‎‡a Author's Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).‏
670 ‎‡a Author's Trastuzumab for early breast cancer: current status and future directions.‏
670 ‎‡a Author's Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.‏
670 ‎‡a Author's Trastuzumab (herceptin) for early-stage breast cancer‏
670 ‎‡a Author's Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience‏
670 ‎‡a Author's Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer‏
670 ‎‡a Author's Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial‏
670 ‎‡a Author's Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials‏
670 ‎‡a Author's Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis‏
670 ‎‡a Author's Twenty years of anti-HER2 therapy-associated cardiotoxicity‏
670 ‎‡a Author's Use of adjuvant chemotherapy‏
670 ‎‡a Author's Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.‏
670 ‎‡a Author's Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)‏
909 ‎‡a (scopus) 12446367900‏ ‎‡9 1‏
909 ‎‡a (orcid) 0000000195014509‏ ‎‡9 1‏
919 ‎‡a angiogenesisandcanceracrosstalkbetweenbasicscienceandclinicaltrialsthedoutdesparadigm‏ ‎‡A Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm).‏ ‎‡9 1‏
919 ‎‡a analysisofregionaltimelinestosetupaglobalphase3clinicaltrialinbreastcancertheadjuvantlapatinibandortrastuzumabtreatmentoptimizationexperience‏ ‎‡A Analysis of regional timelines to set up a global phase III clinical trial in breast cancer: the adjuvant lapatinib and/or trastuzumab treatment optimization experience‏ ‎‡9 1‏
919 ‎‡a updateonparpinhibitorsmovingtotheadjuvantsetting‏ ‎‡A An update on PARP inhibitors--moving to the adjuvant setting‏ ‎‡9 1‏
919 ‎‡a exploratoryanalysisofthefactorsleadingtodelaysincancerdrugreimbursementintheeuropeanunionthetrastuzumabcase‏ ‎‡A An exploratory analysis of the factors leading to delays in cancer drug reimbursement in the European Union: the trastuzumab case.‏ ‎‡9 1‏
919 ‎‡a adjuvanttrastuzumaba10yearoverviewofitsbenefit‏ ‎‡A Adjuvant trastuzumab: a 10-year overview of its benefit.‏ ‎‡9 1‏
919 ‎‡a adjuvantpertuzumabandtrastuzumabinearlyher2positivebreastcancer‏ ‎‡A Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer‏ ‎‡9 1‏
919 ‎‡a adjuvantletrozoleandtamoxifenaloneorsequentiallyforpostmenopausalwomenwithhormonereceptorpositivebreastcancerlongtermfollowupofthebig198trial‏ ‎‡A Adjuvant Letrozole and Tamoxifen Alone or Sequentially for Postmenopausal Women With Hormone Receptor-Positive Breast Cancer: Long-Term Follow-Up of the BIG 1-98 Trial‏ ‎‡9 1‏
919 ‎‡a adjuvantlapatinibandtrastuzumabforearlyhumanepidermalgrowthfactorreceptor2positivebreastcancerresultsfromtherandomizedphase3adjuvantlapatinibandortrastuzumabtreatmentoptimizationtrial‏ ‎‡A Adjuvant Lapatinib and Trastuzumab for Early Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Results From the Randomized Phase III Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization Trial‏ ‎‡9 1‏
919 ‎‡a adjuvantchemotherapyin2005standardsandbeyond‏ ‎‡A Adjuvant chemotherapy in 2005: standards and beyond.‏ ‎‡9 1‏
919 ‎‡a adjuvantantiher2therapytreatmentrelatedamenorrheaandsurvivalinpremenopausalher2positiveearlybreastcancerpatients‏ ‎‡A Adjuvant Anti-HER2 Therapy, Treatment-Related Amenorrhea, and Survival in Premenopausal HER2-Positive Early Breast Cancer Patients‏ ‎‡9 1‏
919 ‎‡a achievementsinsystemictherapiesinthepregenomicerainmetastaticbreastcancer‏ ‎‡A Achievements in systemic therapies in the pregenomic era in metastatic breast cancer.‏ ‎‡9 1‏
919 ‎‡a pooledanalysisofthecardiaceventsinthetrastuzumabadjuvanttrials‏ ‎‡A A pooled analysis of the cardiac events in the trastuzumab adjuvant trials‏ ‎‡9 1‏
919 ‎‡a 2yearsversus1yearofadjuvanttrastuzumabforher2positivebreastcancerheraanopenlabelrandomisedcontrolledtrial‏ ‎‡A 2 years versus 1 year of adjuvant trastuzumab for HER2-positive breast cancer (HERA): an open-label, randomised controlled trial‏ ‎‡9 1‏
919 ‎‡a 18ffdgpetctforearlypredictionofresponsetoneoadjuvantlapatinibtrastuzumabandtheircombinationinher2positivebreastcancerresultsfromneoaltto‏ ‎‡A 18F-FDG PET/CT for early prediction of response to neoadjuvant lapatinib, trastuzumab, and their combination in HER2-positive breast cancer: results from Neo-ALTTO.‏ ‎‡9 1‏
919 ‎‡a 11yearsfollowupoftrastuzumabafteradjuvantchemotherapyinher2positiveearlybreastcancerfinalanalysisoftheherceptinadjuvantheratrial‏ ‎‡A 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial‏ ‎‡9 1‏
919 ‎‡a arewehertingforinnovationinneoadjuvantbreastcancertrialdesign‏ ‎‡A Are we HER-ting for innovation in neoadjuvant breast cancer trial design?‏ ‎‡9 1‏
919 ‎‡a associationofp27andcyclind1expressionandbenefitfromadjuvanttrastuzumabtreatmentinher2positiveearlybreastcanceratransherastudy‏ ‎‡A Association of p27 and Cyclin D1 Expression and Benefit from Adjuvant Trastuzumab Treatment in HER2-Positive Early Breast Cancer: A TransHERA Study.‏ ‎‡9 1‏
919 ‎‡a associationoftcellreceptorrepertoireusewithresponsetocombinedtrastuzumablapatinibtreatmentofher2positivebreastcancersecondaryanalysisoftheneoalttorandomizedclinicaltrial‏ ‎‡A Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer: Secondary Analysis of the NeoALTTO Randomized Clinical Trial‏ ‎‡9 1‏
919 ‎‡a atezolizumabinmetastatictriplenegativebreastcancerimpassion130and131trialshowtoexplaindifferentresults‏ ‎‡A Atezolizumab in metastatic triple-negative breast cancer: IMpassion130 and 131 trials - how to explain different results?‏ ‎‡9 1‏
919 ‎‡a bevacizumabandbreastcancerametaanalysisof1linephase3studiesandacriticalreappraisalofavailableevidence‏ ‎‡A Bevacizumab and Breast Cancer: A Meta-Analysis of First-Line Phase III Studies and a Critical Reappraisal of Available Evidence‏ ‎‡9 1‏
919 ‎‡a beyondtrastuzumabnewtreatmentoptionsforher2positivebreastcancer‏ ‎‡A Beyond trastuzumab: new treatment options for HER2-positive breast cancer‏ ‎‡9 1‏
919 ‎‡a weeklycarboplatinplusneoadjuvantanthracyclinetaxanebasedregimeninearlytriplenegativebreastcanceraprospectivephase2trialbythebreastcancertaskforceofthebelgiansocietyofmedicaloncologybsmo‏ ‎‡A Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)‏ ‎‡9 1‏
919 ‎‡a useofadjuvantchemotherapyctandradiotherapyrtinincompletelyresectedr1earlystagenonsmallcelllungcancernsclcaeuropeansurveyconductedbytheeuropeansocietyformedicaloncologyesmoyoungoncologistscommittee‏ ‎‡A Use of adjuvant chemotherapy (CT) and radiotherapy (RT) in incompletely resected (R1) early stage Non-Small Cell Lung Cancer (NSCLC): a European survey conducted by the European Society for Medical Oncology (ESMO) young oncologists committee.‏ ‎‡9 1‏
919 ‎‡a useofadjuvantchemotherapy‏ ‎‡A Use of adjuvant chemotherapy‏ ‎‡9 1‏
919 ‎‡a 20yearsofantiher2therapyassociatedcardiotoxicity‏ ‎‡A Twenty years of anti-HER2 therapy-associated cardiotoxicity‏ ‎‡9 1‏
919 ‎‡a tumourinfiltratinglymphocytesinnoninvasivebreastcancerasystematicreviewandmetaanalysis‏ ‎‡A Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a tumorinfiltratinglymphocytesinpatientswithher2positivebreastcancertreatedwithneoadjuvantchemotherapyplustrastuzumablapatinibortheircombinationametaanalysisofrandomizedcontrolledtrials‏ ‎‡A Tumor-infiltrating lymphocytes in patients with HER2-positive breast cancer treated with neoadjuvant chemotherapy plus trastuzumab, lapatinib or their combination: A meta-analysis of randomized controlled trials‏ ‎‡9 1‏
919 ‎‡a tumorinfiltratinglymphocytesandassociationswithpathologicalcompleteresponseandeventfreesurvivalinher2positiveearlystagebreastcancertreatedwithlapatinibandtrastuzumabasecondaryanalysisoftheneoalttotrial‏ ‎‡A Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial‏ ‎‡9 1‏
919 ‎‡a treatmentoptionsinanthracyclineandortaxanepretreatedpatientswithmetastaticbreastcancer‏ ‎‡A Treatment Options in Anthracycline and/or Taxane Pretreated Patients with Metastatic Breast Cancer‏ ‎‡9 1‏
919 ‎‡a trastuzumabretreatmentfollowingadjuvanttrastuzumabandtheimportanceofdistantdiseasefreeintervaltheheratrialexperience‏ ‎‡A Trastuzumab re-treatment following adjuvant trastuzumab and the importance of distant disease-free interval: the HERA trial experience‏ ‎‡9 1‏
919 ‎‡a trastuzumabherceptinforearlystagebreastcancer‏ ‎‡A Trastuzumab (herceptin) for early-stage breast cancer‏ ‎‡9 1‏
919 ‎‡a trastuzumabforpatientswithher2positivebreastcancerdeliverydurationandcombinationtherapies‏ ‎‡A Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.‏ ‎‡9 1‏
919 ‎‡a trastuzumabforearlybreastcancercurrentstatusandfuturedirections‏ ‎‡A Trastuzumab for early breast cancer: current status and future directions.‏ ‎‡9 1‏
919 ‎‡a trastuzumabassociatedcardiaceventsat8yearsofmedianfollowupintheherceptinadjuvanttrialbig101‏ ‎‡A Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).‏ ‎‡9 1‏
919 ‎‡a trastuzumabassociatedcardiaceventsat8yearsofmedianfollowupintheherceptinadjuvanttrial‏ ‎‡A Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial‏ ‎‡9 1‏
919 ‎‡a threatposedbyunprovendrugsinmedicaloncology‏ ‎‡A Threat posed by unproven drugs in medical oncology‏ ‎‡9 1‏
919 ‎‡a useofbreastimagingforpredictingresponsetoneoadjuvantlapatinibtrastuzumabandtheircombinationinher2positivebreastcancerresultsfromneoaltto‏ ‎‡A The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO.‏ ‎‡9 1‏
919 ‎‡a prognosticroleofandrogenreceptorinpatientswithearlystagebreastcancerametaanalysisofclinicalandgeneexpressiondata‏ ‎‡A The Prognostic Role of Androgen Receptor in Patients with Early-Stage Breast Cancer: A Meta-analysis of Clinical and Gene Expression Data‏ ‎‡9 1‏
919 ‎‡a prognosticperformanceofadjuvantonlineandnottinghamprognosticindexinyoungbreastcancerpatients‏ ‎‡A The prognostic performance of Adjuvant! Online and Nottingham Prognostic Index in young breast cancer patients.‏ ‎‡9 1‏
919 ‎‡a beyondtrastuzumabovercomingresistancetotargetedher2therapyinbreastcancer‏ ‎‡A Beyond trastuzumab: overcoming resistance to targeted HER-2 therapy in breast cancer‏ ‎‡9 1‏
919 ‎‡a newgenerationofbreastcancerclinicaltrialstherightdrugfortherighttarget‏ ‎‡A The new generation of breast cancer clinical trials: the right drug for the right target‏ ‎‡9 1‏
919 ‎‡a landscapeofmedicaloncologyineuropeby‏ ‎‡A The landscape of medical oncology in Europe by 2020.‏ ‎‡9 1‏
919 ‎‡a impactofcyclindependentkinase4and6inhibitorscdk46iontheincidenceofalopeciainpatientswithmetastaticbreastcancerbc‏ ‎‡A The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC)‏ ‎‡9 1‏
919 ‎‡a effectofbodymassindexonoverallanddiseasefreesurvivalinnodepositivebreastcancerpatientstreatedwithdocetaxelanddoxorubicincontainingadjuvantchemotherapytheexperienceofthebig0298trial‏ ‎‡A The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial‏ ‎‡9 1‏
919 ‎‡a 41geneclassifiertrarpredictsresponseofher2positivebreastcancerpatientsintheneoalttostudy‏ ‎‡A The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study‏ ‎‡9 1‏
919 ‎‡a 17q12q21ampliconher2andtopoisomeraseiialphaandtheirimportancetothebiologyofsolidtumours‏ ‎‡A The 17q12-q21 amplicon: Her2 and topoisomerase-IIalpha and their importance to the biology of solid tumours.‏ ‎‡9 1‏
919 ‎‡a targetingthepi3kaktmtorandrafmekerkpathwaysinthetreatmentofbreastcancer‏ ‎‡A Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer‏ ‎‡9 1‏
919 ‎‡a targetedtherapyforbreastcancerinolderpatients‏ ‎‡A Targeted therapy for breast cancer in older patients‏ ‎‡9 1‏
919 ‎‡a targetedtherapiesinbreastcancerareheartandvesselsalsobeingtargeted‏ ‎‡A Targeted therapies in breast cancer: are heart and vessels also being targeted?‏ ‎‡9 1‏
919 ‎‡a survivaloutcomesoftheneoalttostudybig106updatedresultsofarandomisedmulticenterphase3neoadjuvantclinicaltrialinpatientswithher2positiveprimarybreastcancer‏ ‎‡A Survival outcomes of the NeoALTTO study (BIG 1-06): updated results of a randomised multicenter phase III neoadjuvant clinical trial in patients with HER2-positive primary breast cancer‏ ‎‡9 1‏
919 ‎‡a surgeryoftheprimarytumourinpatientspresentingwithdenovometastaticbreastcancertodoornottodo‏ ‎‡A Surgery of the primary tumour in patients presenting with de novo metastatic breast cancer: to do or not to do?‏ ‎‡9 1‏
919 ‎‡a supportivecareaftercurativetreatmentforbreastcancersurvivorshipcareresourceallocationsinlowandmiddleincomecountriesabreasthealthglobalinitiative2013consensusstatement‏ ‎‡A Supportive care after curative treatment for breast cancer (survivorship care): resource allocations in low- and middle-income countries. A Breast Health Global Initiative 2013 consensus statement‏ ‎‡9 1‏
919 ‎‡a singleagentparpinhibitorsforthetreatmentofpatientswithbrcamutatedher2negativemetastaticbreastcancerasystematicreviewandmetaanalysis‏ ‎‡A Single-agent PARP inhibitors for the treatment of patients with BRCA-mutated HER2-negative metastatic breast cancer: a systematic review and meta-analysis.‏ ‎‡9 1‏
919 ‎‡a shrinkingthetumorshrinkingthepatientsamplesizetheearlydisclosuredilemma‏ ‎‡A Shrinking the tumor, shrinking the patient sample size: the early disclosure dilemma‏ ‎‡9 1‏
919 ‎‡a sequentialorconcurrentadministrationoftrastuzumabinearlybreastcancertooearlytojudge‏ ‎‡A Sequential or Concurrent Administration of Trastuzumab in Early Breast Cancer? Too Early to Judge‏ ‎‡9 1‏
919 ‎‡a roleoftroponins1andtandnterminalprohormoneofbrainnatriureticpeptideinmonitoringcardiacsafetyofpatientswithearlystagehumanepidermalgrowthfactorreceptor2positivebreastcancerreceivingtrastuzumabaherceptinadjuvantst‏ ‎‡A Role of Troponins I and T and N-Terminal Prohormone of Brain Natriuretic Peptide in Monitoring Cardiac Safety of Patients With Early-Stage Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Trastuzumab: A Herceptin Adjuvant St‏ ‎‡9 1‏
919 ‎‡a roleofthemultidisciplinaryteaminbreastcancermanagementresultsfromalargeinternationalsurveyinvolving39countries‏ ‎‡A Role of the multidisciplinary team in breast cancer management: results from a large international survey involving 39 countries.‏ ‎‡9 1‏
919 ‎‡a rnasequencingtopredictresponsetoneoadjuvantantiher2therapyasecondaryanalysisoftheneoalttorandomizedclinicaltrial‏ ‎‡A RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial.‏ ‎‡9 1‏
919 ‎‡a riskofadverseeventswiththeadditionoftargetedagentstoendocrinetherapyinpatientswithhormonereceptorpositivemetastaticbreastcancerasystematicreviewandmetaanalysis‏ ‎‡A Risk of adverse events with the addition of targeted agents to endocrine therapy in patients with hormone receptor-positive metastatic breast cancer: A systematic review and meta-analysis.‏ ‎‡9 1‏
919 ‎‡a riskfactorsforthedevelopmentofbrainmetastasesinpatientswithher2positivebreastcancer‏ ‎‡A Risk factors for the development of brain metastases in patients with HER2-positive breast cancer‏ ‎‡9 1‏
919 ‎‡a reviewsideeffectsofapprovedmoleculartargetedtherapiesinsolidcancers‏ ‎‡A Review: side effects of approved molecular targeted therapies in solid cancers.‏ ‎‡9 1‏
919 ‎‡a reproductivepotentialandperformanceoffertilitypreservationstrategiesinbrcamutatedbreastcancerpatients‏ ‎‡A Reproductive potential and performance of fertility preservation strategies in BRCA-mutated breast cancer patients‏ ‎‡9 1‏
919 ‎‡a replyto100fontanellaetal‏ ‎‡A Reply to C. Fontanella et al.‏ ‎‡9 1‏
919 ‎‡a regionalnodalirradiationafterbreastconservingsurgeryforearlyher2positivebreastcancerresultsofasubanalysisfromthealttotrial‏ ‎‡A Regional Nodal Irradiation After Breast Conserving Surgery for Early HER2-Positive Breast Cancer: Results of a Subanalysis From the ALTTO Trial.‏ ‎‡9 1‏
919 ‎‡a recurrencedynamicsofbreastcanceraccordingtobaselinebodymassindex‏ ‎‡A Recurrence dynamics of breast cancer according to baseline body mass index‏ ‎‡9 1‏
919 ‎‡a radiologicalevaluationofresponsetoimmunotherapyinbraintumorswherearewenowandwherearewegoing‏ ‎‡A Radiological evaluation of response to immunotherapy in brain tumors: Where are we now and where are we going?‏ ‎‡9 1‏
919 ‎‡a pulmonaryepithelialpermeabilityinpatientstreatedwithbleomycincontainingchemotherapydetectedbytechnetium99mdiethylenetriaminepentaaceticacidaerosol99mtcdtpascintigraphy‏ ‎‡A Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol (99mTc-DTPA) scintigraphy‏ ‎‡9 1‏
919 ‎‡a pulmonaryepithelialpermeabilityinpatientstreatedwithbleomycincontainingchemotherapydetectedbytechnetium99mdiethylenetriaminepentaaceticacidaerosol‏ ‎‡A Pulmonary epithelial permeability in patients treated with bleomycin containing chemotherapy detected by technetium-99m diethylene triamine penta-acetic acid aerosol‏ ‎‡9 1‏
919 ‎‡a prognosticroleofdistantdiseasefreeintervalfromcompletionofadjuvanttrastuzumabinher2positiveearlybreastcanceranalysisfromthealttobig206trial‏ ‎‡A Prognostic role of distant disease-free interval from completion of adjuvant trastuzumab in HER2-positive early breast cancer: analysis from the ALTTO (BIG 2-06) trial‏ ‎‡9 1‏
919 ‎‡a prognosticpredictiveabilitiesandconcordanceofbcl2andtp53proteinexpressioninprimarybreastcancersandaxillarylymphnodesaretrospectiveanalysisofthebelgian3armstudyevaluatinganthracyclinevscmfadjuvantchemotherapy‏ ‎‡A Prognostic, predictive abilities and concordance of BCL2 and TP53 protein expression in primary breast cancers and axillary lymph-nodes: a retrospective analysis of the Belgian three arm study evaluating anthracycline vs CMF adjuvant chemotherapy‏ ‎‡9 1‏
919 ‎‡a prognosticimpactofpregnancyafterbreastcanceraccordingtoestrogenreceptorstatusamulticenterretrospectivestudy‏ ‎‡A Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study‏ ‎‡9 1‏
919 ‎‡a prognosticandpredictivevalueoftumorinfiltratinglymphocytesinaphase3randomizedadjuvantbreastcancertrialinnodepositivebreastcancercomparingtheadditionofdocetaxeltodoxorubicinwithdoxorubicinbasedchemotherapybig0298‏ ‎‡A Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98‏ ‎‡9 1‏
919 ‎‡a prognosticandpredictivevalueoftp53mutationsinnodepositivebreastcancerpatientstreatedwithanthracyclineoranthracyclinetaxanebasedadjuvanttherapyresultsfromthebig0298phase3trial‏ ‎‡A Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial‏ ‎‡9 1‏
919 ‎‡a professionalburnoutineuropeanyoungoncologistsresultsoftheeuropeansocietyformedicaloncologyesmoyoungoncologistscommitteeburnoutsurvey‏ ‎‡A Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey.‏ ‎‡9 1‏
919 ‎‡a professionalburnoutineuropeanyoungoncologistsresultsoftheeuropeansocietyformedicaloncology‏ ‎‡A Professional burnout in European young oncologists: results of the European Society for Medical Oncology‏ ‎‡9 1‏
919 ‎‡a preventionmonitoringandmanagementofcardiacdysfunctioninpatientswithmetastaticbreastcancer‏ ‎‡A Prevention, Monitoring, and Management of Cardiac Dysfunction in Patients with Metastatic Breast Cancer‏ ‎‡9 1‏
919 ‎‡a pregnancyoccurringduringorfollowingadjuvanttrastuzumabinpatientsenrolledintheheratrialbig0101‏ ‎‡A Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01).‏ ‎‡9 1‏
919 ‎‡a pregnancyoccurringduringorfollowingadjuvanttrastuzumabinpatientsenrolledintheheratrial‏ ‎‡A Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial‏ ‎‡9 1‏
919 ‎‡a pregnanciesduringandaftertrastuzumabandorlapatinibinpatientswithhumanepidermalgrowthfactorreceptor2positiveearlybreastcanceranalysisfromtheneoalttobig106andalttobig206trials‏ ‎‡A Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO (BIG 1-06) and ALTTO (BIG 2-06) trials‏ ‎‡9 1‏
919 ‎‡a pregnanciesduringandaftertrastuzumabandorlapatinibinpatientswithhumanepidermalgrowthfactorreceptor2positiveearlybreastcanceranalysisfromtheneoaltto‏ ‎‡A Pregnancies during and after trastuzumab and/or lapatinib in patients with human epidermal growth factor receptor 2-positive early breast cancer: analysis from the NeoALTTO‏ ‎‡9 1‏
919 ‎‡a postmastectomyradiationtherapyinwomenwitht1t2tumorsand1to3positivelymphnodesanalysisofthebreastinternationalgroup0298trial‏ ‎‡A Postmastectomy Radiation Therapy in Women with T1-T2 Tumors and 1 to 3 Positive Lymph Nodes: Analysis of the Breast International Group 02-98 Trial‏ ‎‡9 1‏
919 ‎‡a postneoadjuvanttreatmentandthemanagementofresidualdiseaseinbreastcancerstateoftheartandperspectives‏ ‎‡A Post-neoadjuvant treatment and the management of residual disease in breast cancer: state of the art and perspectives‏ ‎‡9 1‏
919 ‎‡a platinumbasedneoadjuvantchemotherapyintriplenegativebreastcancerasystematicreviewandmetaanalysis‏ ‎‡A Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a plasmamirnalevelsforpredictingtherapeuticresponsetoneoadjuvanttreatmentinher2positivebreastcancerresultsfromtheneoalttotrial‏ ‎‡A Plasma miRNA Levels for Predicting Therapeutic Response to Neoadjuvant Treatment in HER2-positive Breast Cancer: Results from the NeoALTTO Trial‏ ‎‡9 1‏
919 ‎‡a planningcancercontrolinlatinamericaandthecaribbean‏ ‎‡A Planning cancer control in Latin America and the Caribbean‏ ‎‡9 1‏
919 ‎‡a pik3camutationsareassociatedwithdecreasedbenefittoneoadjuvanthumanepidermalgrowthfactorreceptor2targetedtherapiesinbreastcancer‏ ‎‡A PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer‏ ‎‡9 1‏
919 ‎‡a phosphoethanolamineandthedangerofunprovendrugs‏ ‎‡A Phosphoethanolamine and the danger of unproven drugs‏ ‎‡9 1‏
919 ‎‡a phase1trialcombiningtemozolomidepluslapatinibforthetreatmentofbrainmetastasesinpatientswithher2positivemetastaticbreastcancerthelaptemtrial‏ ‎‡A Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trial.‏ ‎‡9 1‏
919 ‎‡a pharmacologicmeasuresinthepreventionofleftventriculardysfunctionassociatedwithmoleculartargetedtherapiesinthetreatmentofcancerpatients‏ ‎‡A Pharmacologic measures in the prevention of left ventricular dysfunction associated with molecular-targeted therapies in the treatment of cancer patients‏ ‎‡9 1‏
919 ‎‡a pertuzumabinher2positiveearlybreastcancercurrentuseandperspectives‏ ‎‡A Pertuzumab in HER2-positive early breast cancer: current use and perspectives‏ ‎‡9 1‏
919 ‎‡a persephoneimplicationsforclinicalpracticein‏ ‎‡A PERSEPHONE - implications for clinical practice in 2019‏ ‎‡9 1‏
919 ‎‡a patternofrashdiarrheaandhepatictoxicitiessecondarytolapatinibandtheirassociationwithageandresponsetoneoadjuvanttherapyanalysisfromtheneoalttotrial‏ ‎‡A Pattern of rash, diarrhea, and hepatic toxicities secondary to lapatinib and their association with age and response to neoadjuvant therapy: analysis from the NeoALTTO trial‏ ‎‡9 1‏
919 ‎‡a pstat3inluminalbreastcancerintegratedrnaproteinpooledanalysisandresultsfromthebig298phase3trial‏ ‎‡A p-STAT3 in luminal breast cancer: Integrated RNA-protein pooled analysis and results from the BIG 2-98 phase III trial.‏ ‎‡9 1‏
919 ‎‡a overallsurvivalbenefitforsequentialdoxorubicindocetaxelcomparedwithconcurrentdoxorubicinanddocetaxelinnodepositivebreastcancer8yearresultsofthebreastinternationalgroup0298phase3trial‏ ‎‡A Overall survival benefit for sequential doxorubicin–docetaxel compared with concurrent doxorubicin and docetaxel in node-positive breast cancer—8-year results of the Breast International Group 02-98 phase III trial†‏ ‎‡9 1‏
919 ‎‡a ovarianfunctionsuppressioninpremenopausalwomenwithearlystagebreastcancer‏ ‎‡A Ovarian Function Suppression in Premenopausal Women with Early-Stage Breast Cancer.‏ ‎‡9 1‏
919 ‎‡a optimox1inadvancedcolorectalcancerlackofevidenceforastopand5strategy‏ ‎‡A OPTIMOX1 in Advanced Colorectal Cancer: Lack of Evidence for a Stop-and-Go Strategy‏ ‎‡9 1‏
919 ‎‡a oncofertilitycounsellinginpremenopausalwomenwithher2positivebreastcancer‏ ‎‡A Oncofertility counselling in premenopausal women with HER2-positive breast cancer‏ ‎‡9 1‏
919 ‎‡a noveltherapeuticsinbreastcancerlookingtothefuture‏ ‎‡A Novel therapeutics in breast cancer—Looking to the future‏ ‎‡9 1‏
919 ‎‡a nonhodgkinslymphomainthethyroidcasereport‏ ‎‡A [Non-Hodgkin's lymphoma in the thyroid: case report]‏ ‎‡9 1‏
919 ‎‡a neoadjuvantletrozoleplustaselisibversusletrozoleplusplaceboinpostmenopausalwomenwithoestrogenreceptorpositiveher2negativeearlystagebreastcancerloreleiamulticentrerandomiseddoubleblindplacebocontrolledphase2tri‏ ‎‡A Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 tri‏ ‎‡9 1‏
919 ‎‡a neoadjuvantchemotherapyandtrastuzumabversusneoadjuvantchemotherapyfollowedbypostoperativetrastuzumabforpatientswithher2positivebreastcancer‏ ‎‡A Neoadjuvant chemotherapy and trastuzumab versus neoadjuvant chemotherapy followed by post-operative trastuzumab for patients with HER2-positive breast cancer‏ ‎‡9 1‏
919 ‎‡a neoadjuvantchemotherapyandtargetedtherapiesapromisingstrategy‏ ‎‡A Neoadjuvant Chemotherapy and Targeted Therapies: a Promising Strategy‏ ‎‡9 1‏
919 ‎‡a neoadjuvantanthracyclineandtrastuzumabforbreastcancerisconcurrenttreatmentsafe‏ ‎‡A Neoadjuvant anthracycline and trastuzumab for breast cancer: is concurrent treatment safe?‏ ‎‡9 1‏
919 ‎‡a multifactorialapproachtopredictingresistancetoanthracyclines‏ ‎‡A Multifactorial approach to predicting resistance to anthracyclines‏ ‎‡9 1‏
919 ‎‡a motherhoodafterbreastcancersearchingforladolcevita‏ ‎‡A Motherhood after breast cancer: searching for la dolce vita.‏ ‎‡9 1‏
919 ‎‡a moleculartargetedtherapiesinbreastcancerwherearewenow‏ ‎‡A Molecular targeted therapies in breast cancer: where are we now?‏ ‎‡9 1‏
919 ‎‡a molecularprofilingofatumorofunknownorigin‏ ‎‡A Molecular Profiling of a Tumor of Unknown Origin‏ ‎‡9 1‏
919 ‎‡a molecularmarkersofheadandnecksquamouscellcarcinomapromisingsignsinneedofprospectiveevaluation‏ ‎‡A Molecular markers of head and neck squamous cell carcinoma: promising signs in need of prospective evaluation‏ ‎‡9 1‏
919 ‎‡a metronomicchemotherapycombinedwithendocrinetherapyarewechallengingsomedogmas‏ ‎‡A Metronomic chemotherapy combined with endocrine therapy: are we challenging some dogmas?‏ ‎‡9 1‏
919 ‎‡a menopausalhormonetherapyuseinrelationtobreastcancerincidencein11europeancountries‏ ‎‡A Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries‏ ‎‡9 1‏
919 ‎‡a menopausalhormonetherapyusein17europeancountriesduringthelastdecade‏ ‎‡A Menopausal hormone therapy use in 17 European countries during the last decade‏ ‎‡9 1‏
919 ‎‡a malebreastcancerfindingthewayinthisuncommonpath‏ ‎‡A Male breast cancer: finding the way in this uncommon path.‏ ‎‡9 1‏
919 ‎‡a magnitudeoftrastuzumabbenefitinpatientswithher2positiveinvasivelobularbreastcarcinomaresultsfromtheheratrial‏ ‎‡A Magnitude of trastuzumab benefit in patients with HER2-positive, invasive lobular breast carcinoma: results from the HERA trial‏ ‎‡9 1‏
919 ‎‡a luminalbbreastcancermolecularcharacterizationclinicalmanagementandfutureperspectives‏ ‎‡A Luminal B breast cancer: molecular characterization, clinical management, and future perspectives‏ ‎‡9 1‏
919 ‎‡a longertermassessmentoftrastuzumabrelatedcardiacadverseeventsintheherceptinadjuvantheratrial‏ ‎‡A Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.‏ ‎‡9 1‏
919 ‎‡a longertermassessmentoftrastuzumabrelatedcardiacadverseeventsintheherceptinadjuvant‏ ‎‡A Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant‏ ‎‡9 1‏
919 ‎‡a longtermtoxiceffectsofadjuvantchemotherapyinbreastcancer‏ ‎‡A Long-term toxic effects of adjuvant chemotherapy in breast cancer.‏ ‎‡9 1‏
919 ‎‡a longtermsafetyofpregnancyfollowingbreastcanceraccordingtoestrogenreceptorstatus‏ ‎‡A Long-term Safety of Pregnancy Following Breast Cancer According to Estrogen Receptor Status.‏ ‎‡9 1‏
919 ‎‡a longtermbenefitofhighdoseepirubicininadjuvantchemotherapyfornodepositivebreastcancer15yearefficacyresultsofthebelgianmulticentrestudy‏ ‎‡A Long-term benefit of high-dose epirubicin in adjuvant chemotherapy for node-positive breast cancer: 15-year efficacy results of the Belgian multicentre study.‏ ‎‡9 1‏
919 ‎‡a lessonslearnedatsabcs2019andto2fromimmunotherapyinbreastcancer‏ ‎‡A Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer‏ ‎‡9 1‏
919 ‎‡a larotaxelbroadeningtheroadwithnewtaxanes‏ ‎‡A Larotaxel: broadening the road with new taxanes‏ ‎‡9 1‏
919 ‎‡a lapatinibwithtrastuzumabforher2positiveearlybreastcancerneoalttosurvivaloutcomesofarandomisedopenlabelmulticentrephase3trialandtheirassociationwithpathologicalcompleteresponse‏ ‎‡A Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response‏ ‎‡9 1‏
919 ‎‡a lapatinibwithtrastuzumabforher2positiveearlybreastcancerneoalttoarandomisedopenlabelmulticentrephase3trial‏ ‎‡A Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial‏ ‎‡9 1‏
919 ‎‡a lapatinibrelatedrashandbreastcanceroutcomeinthealttophase3randomizedtrial‏ ‎‡A Lapatinib-Related Rash and Breast Cancer Outcome in the ALTTO Phase III Randomized Trial‏ ‎‡9 1‏
919 ‎‡a jumpinghigherisitstillpossiblethealttotrialchallenge‏ ‎‡A Jumping higher: is it still possible? The ALTTO trial challenge‏ ‎‡9 1‏
919 ‎‡a intrathecaladministrationoftrastuzumabforthetreatmentofmeningealcarcinomatosisinher2positivemetastaticbreastcancerasystematicreviewandpooledanalysis‏ ‎‡A Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis‏ ‎‡9 1‏
919 ‎‡a internationalexpertconsensusonprimarysystemictherapyinthemanagementofearlybreastcancerhighlightsofthe4symposiumonprimarysystemictherapyinthemanagementofoperablebreastcancercremonaitaly‏ ‎‡A International expert consensus on primary systemic therapy in the management of early breast cancer: highlights of the Fourth Symposium on Primary Systemic Therapy in the Management of Operable Breast Cancer, Cremona, Italy (2010).‏ ‎‡9 1‏
919 ‎‡a informationperceptionwishesandsatisfactioninambulatorycancerpatientsunderactivetreatmentpatientreportedoutcomeswithqlqinfo25‏ ‎‡A Information perception, wishes, and satisfaction in ambulatory cancer patients under active treatment: patient-reported outcomes with QLQ-INFO25.‏ ‎‡9 1‏
919 ‎‡a inreplytobelkacemiandtsoutsou‏ ‎‡A In Reply to Belkacemi and Tsoutsou‏ ‎‡9 1‏
919 ‎‡a improvingqualityoflifeafterbreastcancerdealingwithsymptoms‏ ‎‡A Improving quality of life after breast cancer: dealing with symptoms‏ ‎‡9 1‏
919 ‎‡a impactofsolidcanceroninhospitalmortalityoverallandamongdifferentsubgroupsofpatientswithcovid19anationwidepopulationbasedanalysis‏ ‎‡A Impact of solid cancer on in-hospital mortality overall and among different subgroups of patients with COVID-19: a nationwide, population-based analysis‏ ‎‡9 1‏
919 ‎‡a impactofovarianfunctionsuppressioninpremenopausalwomenwithestrogenreceptorpositiveearlybreastcancer‏ ‎‡A Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer‏ ‎‡9 1‏
919 ‎‡a impactofdiabetesinsulinandmetforminuseontheoutcomeofpatientswithhumanepidermalgrowthfactorreceptor2positiveprimarybreastcanceranalysisfromthealttophase3randomizedtrial‏ ‎‡A Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial.‏ ‎‡9 1‏
919 ‎‡a biomarkersofresponseandresistancetopi3kinhibitorsinestrogenreceptorpositivebreastcancerpatientsandcombinationtherapiesinvolvingpi3kinhibitors‏ ‎‡A Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors‏ ‎‡9 1‏
919 ‎‡a immuneresponsetoantisarscov2primevaccinationinpatientswithcancerasystematicreviewandmetaanalysis‏ ‎‡A Immune response to anti-SARS-CoV-2 prime-vaccination in patients with cancer: a systematic review and meta-analysis‏ ‎‡9 1‏
919 ‎‡a spy2optimisingcancerdrugdevelopmentinthe21stcentury‏ ‎‡A I-SPY 2: optimising cancer drug development in the 21st century.‏ ‎‡9 1‏
919 ‎‡a hurdlesanddelaysinaccesstoanticancerdrugsineurope‏ ‎‡A Hurdles and delays in access to anti-cancer drugs in Europe.‏ ‎‡9 1‏
919 ‎‡a howlongisenoughoptimaltimingofantiher2neutherapyintheadjuvantsettinginearlybreastcancer‏ ‎‡A How Long is Enough - Optimal Timing of Anti-HER2/neu Therapy in the Adjuvant Setting in Early Breast Cancer‏ ‎‡9 1‏
919 ‎‡a highher2expressioncorrelateswithresponsetothecombinationoflapatinibandtrastuzumab‏ ‎‡A High HER2 expression correlates with response to the combination of lapatinib and trastuzumab.‏ ‎‡9 1‏
919 ‎‡a her2positivebreastcancerislostintranslationtimeforpatientcenteredresearch‏ ‎‡A HER2-positive breast cancer is lost in translation: time for patient-centered research‏ ‎‡9 1‏
919 ‎‡a her2overexpressingbreastcancertimeforthecurewithlesschemotherapy‏ ‎‡A HER2-overexpressing breast cancer: time for the cure with less chemotherapy?‏ ‎‡9 1‏
919 ‎‡a her2positivebreastcancerwhatelsebeyondtrastuzumabbasedtherapy‏ ‎‡A HER-2 positive breast cancer: what else beyond trastuzumab-based therapy?‏ ‎‡9 1‏
919 ‎‡a her2asatargetforbreastcancertherapy‏ ‎‡A HER-2 as a target for breast cancer therapy.‏ ‎‡9 1‏
919 ‎‡a guidelinesfortimetoeventendpointdefinitionsinbreastcancertrialsresultsofthedatecaninitiativedefinitionfortheassessmentoftimetoeventendpointsincancertrials‏ ‎‡A Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)†‏ ‎‡9 1‏
919 ‎‡a guidelinesfortimetoeventendpointdefinitionsinbreastcancertrialsresultsofthedatecaninitiative‏ ‎‡A Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative‏ ‎‡9 1‏
919 ‎‡a genomicgradeindexggifeasibilityinroutinepracticeandimpactontreatmentdecisionsinearlybreastcancer‏ ‎‡A Genomic Grade Index (GGI): feasibility in routine practice and impact on treatment decisions in early breast cancer‏ ‎‡9 1‏
919 ‎‡a genomicgradeaddsprognosticvalueininvasivelobularcarcinoma‏ ‎‡A Genomic grade adds prognostic value in invasive lobular carcinoma.‏ ‎‡9 1‏
919 ‎‡a genomewidegeneexpressionprofilingtopredictresistancetoanthracyclinesinbreastcancerpatients‏ ‎‡A Genome-wide gene expression profiling to predict resistance to anthracyclines in breast cancer patients‏ ‎‡9 1‏
919 ‎‡a final10yearresultsofthebreastinternationalgroup298phase3trialandtheroleofki67inpredictingbenefitofadjuvantdocetaxelinpatientswithoestrogenreceptorpositivebreastcancer‏ ‎‡A Final 10-year results of the Breast International Group 2-98 phase III trial and the role of Ki67 in predicting benefit of adjuvant docetaxel in patients with oestrogen receptor positive breast cancer.‏ ‎‡9 1‏
919 ‎‡a brainmetastasesinher2positivebreastcancertheevolvingroleoflapatinib‏ ‎‡A Brain metastases in HER2-positive breast cancer: the evolving role of lapatinib‏ ‎‡9 1‏
919 ‎‡a feasibilitystudyofendotag1atumorendothelialtargetingagentincombinationwithpaclitaxelfollowedbyfecasinductiontherapyinher2negativebreastcancer‏ ‎‡A Feasibility Study of EndoTAG-1, a Tumor Endothelial Targeting Agent, in Combination with Paclitaxel followed by FEC as Induction Therapy in HER2-Negative Breast Cancer‏ ‎‡9 1‏
919 ‎‡a factsandcontroversiesintheuseoftrastuzumabintheadjuvantsetting‏ ‎‡A Facts and controversies in the use of trastuzumab in the adjuvant setting‏ ‎‡9 1‏
919 ‎‡a factorsaffectingsurgicalmanagementfollowingneoadjuvanttherapyinpatientswithprimaryher2positivebreastcancerresultsfromtheneoalttophase3trial‏ ‎‡A Factors affecting surgical management following neoadjuvant therapy in patients with primary HER2-positive breast cancer: results from the NeoALTTO phase III trial.‏ ‎‡9 1‏
919 ‎‡a esmomanagementandtreatmentadaptedrecommendationsinthecovid19erabreastcancer‏ ‎‡A ESMO Management and treatment adapted recommendations in the COVID-19 era: Breast Cancer‏ ‎‡9 1‏
919 ‎‡a er+her2+breastcancerarewereallydeescalating‏ ‎‡A ER+/HER2+ breast cancer: are we really de-escalating?‏ ‎‡9 1‏
919 ‎‡a endocrinetherapybasedtreatmentsinhormonereceptorpositiveher2negativeadvancedbreastcancersystematicreviewandnetworkmetaanalysis‏ ‎‡A Endocrine therapy-based treatments in hormone receptor-positive/HER2-negative advanced breast cancer: systematic review and network meta-analysis‏ ‎‡9 1‏
919 ‎‡a endocrinetherapyandpalbociclibwithinacompassionateuseprograminheavilypretreatedhormonereceptorpositiveher2negativemetastaticbreastcancer‏ ‎‡A Endocrine therapy and palbociclib within a compassionate use program in heavily pretreated hormone receptor-positive, HER2-negative metastatic breast cancer.‏ ‎‡9 1‏
919 ‎‡a endoflifecaretheredalertforphysicians‏ ‎‡A End-of-life care: the red alert for physicians‏ ‎‡9 1‏
919 ‎‡a emergingtreatmentsforher2positiveearlystagebreastcancerfocusonneratinib‏ ‎‡A Emerging treatments for HER2-positive early-stage breast cancer: focus on neratinib.‏ ‎‡9 1‏
919 ‎‡a efficacyofantiher2agentsincombinationwithadjuvantorneoadjuvantchemotherapyforearlyandlocallyadvancedher2positivebreastcancerpatientsanetworkmetaanalysis‏ ‎‡A Efficacy of Anti-HER2 Agents in Combination With Adjuvant or Neoadjuvant Chemotherapy for Early and Locally Advanced HER2-Positive Breast Cancer Patients: A Network Meta-Analysis.‏ ‎‡9 1‏
919 ‎‡a efficacyofadjuvanttrastuzumabforpatientswithhumanepidermalgrowthfactorreceptor2positiveearlybreastcancerandtumors2900ametaanalysisoftherandomizedtrastuzumabtrials‏ ‎‡A Efficacy of Adjuvant Trastuzumab for Patients With Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer and Tumors ≤ 2 cm: A Meta-Analysis of the Randomized Trastuzumab Trials‏ ‎‡9 1‏
919 ‎‡a effectsofestrogenreceptorandhumanepidermalgrowthfactorreceptor2levelsontheefficacyoftrastuzumabasecondaryanalysisoftheheratrial‏ ‎‡A Effects of Estrogen Receptor and Human Epidermal Growth Factor Receptor-2 Levels on the Efficacy of Trastuzumab: A Secondary Analysis of the HERA Trial‏ ‎‡9 1‏
919 ‎‡a earlymodulationofcirculatingmicrornaslevelsinher2positivebreastcancerpatientstreatedwithtrastuzumabbasedneoadjuvanttherapy‏ ‎‡A Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy‏ ‎‡9 1‏
919 ‎‡a durationofendocrinetherapyanditsimpactontheresultsofadjuvanttrialsinpremenopausalbreastcancerpatients‏ ‎‡A Duration of endocrine therapy and its impact on the results of adjuvant trials in premenopausal breast cancer patients‏ ‎‡9 1‏
919 ‎‡a dualhumanepidermalgrowthfactorreceptor2blockadeanotherstepforwardintreatingpatientswithhumanepidermalgrowthfactorreceptor2positivebreastcancer‏ ‎‡A Dual human epidermal growth factor receptor 2 blockade: another step forward in treating patients with human epidermal growth factor receptor 2-positive breast cancer‏ ‎‡9 1‏
919 ‎‡a dissectingtheheterogeneityoftriplenegativebreastcancer‏ ‎‡A Dissecting the heterogeneity of triple-negative breast cancer‏ ‎‡9 1‏
919 ‎‡a dissectingtheeffectofhormonereceptorstatusinpatientswithher2positiveearlybreastcancerexploratoryanalysisfromthealttobig206randomizedclinicaltrial‏ ‎‡A Dissecting the effect of hormone receptor status in patients with HER2-positive early breast cancer: exploratory analysis from the ALTTO (BIG 2-06) randomized clinical trial‏ ‎‡9 1‏
919 ‎‡a diseasefreesurvivalaccordingtodegreeofher2amplificationforpatientstreatedwithadjuvantchemotherapywithorwithout1yearoftrastuzumabtheheratrial‏ ‎‡A Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial‏ ‎‡9 1‏
919 ‎‡a discrepanciesincancerincidenceandmortalityanditsrelationshiptohealthexpenditureinthe27europeanunionmemberstates‏ ‎‡A Discrepancies in cancer incidence and mortality and its relationship to health expenditure in the 27 European Union member states.‏ ‎‡9 1‏
919 ‎‡a breastcancerachievementsinadjuvantsystemictherapiesinthepregenomicera‏ ‎‡A Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.‏ ‎‡9 1‏
919 ‎‡a breastcancertreatmentinducedcardiotoxicity‏ ‎‡A Breast cancer treatment-induced cardiotoxicity‏ ‎‡9 1‏
919 ‎‡a cardiacassessmentofearlybreastcancerpatients18yearsaftertreatmentwithcyclophosphamidemethotrexatefluorouracilorepirubicinbasedchemotherapy‏ ‎‡A Cardiac assessment of early breast cancer patients 18 years after treatment with cyclophosphamide-, methotrexate-, fluorouracil- or epirubicin-based chemotherapy‏ ‎‡9 1‏
919 ‎‡a cardiacbiomarkersforearlydetectionandpredictionoftrastuzumabandorlapatinibinducedcardiotoxicityinpatientswithher2positiveearlystagebreastcanceraneoalttosubstudy‏ ‎‡A Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study‏ ‎‡9 1‏
919 ‎‡a cardiacbiomarkersforearlydetectionandpredictionoftrastuzumabandorlapatinibinducedcardiotoxicityinpatientswithher2positiveearlystagebreastcanceraneoalttosubstudybig106‏ ‎‡A Cardiac biomarkers for early detection and prediction of trastuzumab and/or lapatinib-induced cardiotoxicity in patients with HER2-positive early-stage breast cancer: a NeoALTTO sub-study (BIG 1-06).‏ ‎‡9 1‏
919 ‎‡a cardiactoxicitywithantiher2therapieswhathavewelearnedsofar‏ ‎‡A Cardiac toxicity with anti-HER-2 therapies: what have we learned so far?‏ ‎‡9 1‏
919 ‎‡a cardiotoxicityofsystemicagentsusedinbreastcancer‏ ‎‡A Cardiotoxicity of systemic agents used in breast cancer‏ ‎‡9 1‏
919 ‎‡a cardiotoxicityoftrastuzumabgivenfor12monthscomparedtoshortertreatmentperiodsasystematicreviewandmetaanalysisof6clinicaltrials‏ ‎‡A Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials‏ ‎‡9 1‏
919 ‎‡a cardiovascularsideeffectsofcancertherapiesapositionstatementfromtheheartfailureassociationoftheeuropeansocietyofcardiology‏ ‎‡A Cardiovascular side effects of cancer therapies: a position statement from the Heart Failure Association of the European Society of Cardiology‏ ‎‡9 1‏
919 ‎‡a careeropportunitiesandbenefitsforyoungoncologistsintheeuropeansocietyformedicaloncology‏ ‎‡A Career opportunities and benefits for young oncologists in the European Society for Medical Oncology‏ ‎‡9 1‏
919 ‎‡a careeropportunitiesandbenefitsforyoungoncologistsintheeuropeansocietyformedicaloncologyesmo‏ ‎‡A Career opportunities and benefits for young oncologists in the European Society for Medical Oncology (ESMO).‏ ‎‡9 1‏
919 ‎‡a cdk46inhibitioninhrpositiveearlybreastcancerareweputtingalleggsin1basket‏ ‎‡A CDK4/6 inhibition in HR-positive early breast cancer: are we putting all eggs in one basket?‏ ‎‡9 1‏
919 ‎‡a cdk46inhibitorsinthetreatmentofpatientswithbreastcancersummaryofamultidisciplinaryroundtablediscussion‏ ‎‡A CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion‏ ‎‡9 1‏
919 ‎‡a choiceofchemotherapyregimenforearlyher2positivebreastcancerinelderlypatients‏ ‎‡A Choice of chemotherapy regimen for early HER2-positive breast cancer in elderly patients‏ ‎‡9 1‏
919 ‎‡a circulatingtumorcellsandresponsetoneoadjuvantpaclitaxelandher2targetedtherapyasubstudyfromtheneoalttophase3trial‏ ‎‡A Circulating tumor cells and response to neoadjuvant paclitaxel and HER2-targeted therapy: a sub-study from the NeoALTTO phase III trial.‏ ‎‡9 1‏
919 ‎‡a circulatingtumordnainher2amplifiedbreastcanceratranslationalresearchsubstudyoftheneoalttophase3trial‏ ‎‡A Circulating Tumor DNA in HER2-Amplified Breast Cancer: A Translational Research Substudy of the NeoALTTO Phase III Trial‏ ‎‡9 1‏
919 ‎‡a clinicalpracticechangingtrialstheherastudyparadigm‏ ‎‡A Clinical practice-changing trials: the HERA study paradigm.‏ ‎‡9 1‏
919 ‎‡a cnsrelapsesinpatientswithher2positiveearlybreastcancerwhohaveandhavenotreceivedadjuvanttrastuzumabaretrospectivesubstudyoftheheratrial‏ ‎‡A CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial‏ ‎‡9 1‏
919 ‎‡a cnsrelapsesinpatientswithher2positiveearlybreastcancerwhohaveandhavenotreceivedadjuvanttrastuzumabaretrospectivesubstudyoftheheratrialbig101‏ ‎‡A CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).‏ ‎‡9 1‏
919 ‎‡a combinationtherapiesforthetreatmentofher2positivebreastcancercurrentandfutureprospects‏ ‎‡A Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects.‏ ‎‡9 1‏
919 ‎‡a comparisonofageneexpressionprofilingstrategytostandardclinicalworkupfordeterminationoftumouroriginincancerofunknownprimary‏ ‎‡A Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary‏ ‎‡9 1‏
919 ‎‡a comparisonofageneexpressionprofilingstrategytostandardclinicalworkupfordeterminationoftumouroriginincancerofunknownprimarycup‏ ‎‡A Comparison of a gene expression profiling strategy to standard clinical work-up for determination of tumour origin in cancer of unknown primary (CUP).‏ ‎‡9 1‏
919 ‎‡a controversialissuesinearlystagebreastcanceraglobalcollaborativesurveysupportedbytheeuropeansocietyformedicaloncologyesmo‏ ‎‡A Controversial issues in early-stage breast cancer: a global collaborative survey, supported by the European Society for Medical Oncology (ESMO)‏ ‎‡9 1‏
919 ‎‡a controversiesinoncologywhichadjuvantendocrinetherapyistobegiventopremenopausalpatientswithhormonereceptorpositivebreastcancer‏ ‎‡A Controversies in oncology: which adjuvant endocrine therapy is to be given to premenopausal patients with hormone receptor-positive breast cancer?‏ ‎‡9 1‏
919 ‎‡a corrigendumtomenopausalhormonetherapyusein17europeancountriesduringthelastdecadematuritas79‏ ‎‡A Corrigendum to “Menopausal hormone therapy use in 17 European countries during the last decade” [Maturitas 79‏ ‎‡9 1‏
919 ‎‡a corrigendumtomenopausalhormonetherapyusein17europeancountriesduringthelastdecade‏ ‎‡A Corrigendum to “Menopausal hormone therapy use in 17 European countries during the last decade” [Maturitas 79 (2014) 287–291]‏ ‎‡9 1‏
919 ‎‡a currentperspectivesofepothilonesinbreastcancer‏ ‎‡A Current perspectives of epothilones in breast cancer.‏ ‎‡9 1‏
919 ‎‡a denosumabinearlystagebreastcancer‏ ‎‡A Denosumab in early-stage breast cancer‏ ‎‡9 1‏
919 ‎‡a areweassumingtoomuchwithourstatisticalassumptionslessonslearnedfromthealttotrial‏ ‎‡A Are we assuming too much with our statistical assumptions? Lessons learned from the ALTTO trial‏ ‎‡9 1‏
919 ‎‡a arelifesavinganticancerdrugsreachingallpatientspatternsanddiscrepanciesoftrastuzumabuseintheeuropeanunionandtheusa‏ ‎‡A Are life-saving anticancer drugs reaching all patients? Patterns and discrepancies of trastuzumab use in the European Union and the USA.‏ ‎‡9 1‏
919 ‎‡a anthracyclineandtaxanebasedchemotherapyversusdocetaxelandcyclophosphamideintheadjuvanttreatmentofher2negativebreastcancerpatientsasystematicreviewandmetaanalysisofrandomizedcontrolledtrials‏ ‎‡A Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials‏ ‎‡9 1‏
943 ‎‡a 202x‏ ‎‡A 2020‏ ‎‡9 1‏
943 ‎‡a 201x‏ ‎‡A 2019‏ ‎‡9 2‏
946 ‎‡a b‏ ‎‡9 1‏
996 ‎‡2 BNF|15437431‏
996 ‎‡2 ISNI|000000006745821X‏
996 ‎‡2 SUDOC|129954608‏
997 ‎‡a 1900 0 flourished 0000 0‏ ‎‡9 1‏